Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

Table 3 Patients with CNS demyelinating diseases and controls according to their serum AQP4-IgG and MOG-IgG mediated complement activation measured by the formation of the terminal complement complex (TCC)

	TCC AQP4-MOG-	TCC AQP4+MOG-	TCC AQP4-MOG+	p-value
Number	69	27	17
Females¹	44 (64%)	25 (93%) *§	11 (65%)	0.017
Disease²
NMO (n = 23)	6 (26%)	15 (65%)	2 (9%)	< 0.001
HR-NMO (n = 33)	17 (52%)	11 (33%)	5 (15%)
ADEM (n = 19)	11 (58%)	0 (0%)	8 (42%)
CIS (n = 14)	12 (86%)	1 (7%)	1 (7%)
MS (n = 10)	10 (100%)	0 (0%)	0 (0%)
CTRL (n = 14)	13 (93%)	0 (0%)	1 (7%)
Age (y)³	38 (8-74)	48 (19-80) *	13 (2-56) *#	< 0.001
AQP4 IgG¹	16 (23%)	27 (100%) *§	0 (0%) *	< 0.001
Titer (1:)³	0	1,280 *§	0	< 0.001
	(0-1,280)	(160-20,480)	(0)
MOG IgG¹	7 (10%)	0 (0%)	17 (100%) *#	< 0.001
Titer (1:)³	0	0	2,560 *#	< 0.001
	(0-2,560)	(0-20)	(640-20,480)

Patients with NMO (n = 23), HR-NMO (n = 33), ADEM (n = 19), CIS (n = 14), MS (n = 10) and CTRL (n = 14) were grouped according to TCC formation: TCC AQP4 and MOG negative patients (AQP4-MOG-), TCC AQP4 positive and MOG negative (AQP4+MOG-) and TCC AQP4 negative and MOG positive (AQP4-MOG+). In detail, the antibody serostatus (AQP4-IgG/MOG-IgG) and titer levels of the patients investigated for TCC formation are listed in the additional file 3. P-value: groups were compared using¹ Fisher's exact test,² Chi-square test and³ Mann-Whitney U test (data are shown as median with range); * statistically different from TCC AQP4-MOG-; # statistically different from TCC AQP4+MOG-; § statistically different from TCC AQP4-MOG+ (p-values were corrected for multiple comparisons). Abbreviations: TCC = terminal complement complex, y = years.

ISSN: 1742-2094